These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 26123589)

  • 1. Mouse models of thyroid cancer: A 2015 update.
    Kirschner LS; Qamri Z; Kari S; Ashtekar A
    Mol Cell Endocrinol; 2016 Feb; 421():18-27. PubMed ID: 26123589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic alterations in thyroid cancer: the role of mouse models.
    Knostman KA; Jhiang SM; Capen CC
    Vet Pathol; 2007 Jan; 44(1):1-14. PubMed ID: 17197619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling thyroid cancer in the mouse.
    Zhu XG; Cheng SY
    Horm Metab Res; 2009 Jun; 41(6):488-99. PubMed ID: 19358084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic mutations in thyroid carcinoma.
    Taccaliti A; Boscaro M
    Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.
    Nikiforova MN; Kimura ET; Gandhi M; Biddinger PW; Knauf JA; Basolo F; Zhu Z; Giannini R; Salvatore G; Fusco A; Santoro M; Fagin JA; Nikiforov YE
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5399-404. PubMed ID: 14602780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of the hu-PBL-SCID mouse model for the investigation of thyroid cancer.
    Gyory F; Mezosi E; Szakall S; Bajnok L; Varga E; Borbely A; Gazdag A; Juhasz I; Lukacs G; Nagy EV
    Exp Clin Endocrinol Diabetes; 2005 Jul; 113(7):359-64. PubMed ID: 16025395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathology and genetics of thyroid carcinoma.
    DeLellis RA
    J Surg Oncol; 2006 Dec; 94(8):662-9. PubMed ID: 17131411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers.
    Burniat A; Jin L; Detours V; Driessens N; Goffard JC; Santoro M; Rothstein J; Dumont JE; Miot F; Corvilain B
    Endocrinology; 2008 Oct; 149(10):5107-17. PubMed ID: 18583418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling anaplastic thyroid carcinoma in the mouse.
    Champa D; Di Cristofano A
    Horm Cancer; 2015 Feb; 6(1):37-44. PubMed ID: 25420535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
    Fagin JA; Matsuo K; Karmakar A; Chen DL; Tang SH; Koeffler HP
    J Clin Invest; 1993 Jan; 91(1):179-84. PubMed ID: 8423216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis.
    Nikiforova MN; Nikiforov YE
    Expert Rev Mol Diagn; 2008 Jan; 8(1):83-95. PubMed ID: 18088233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
    Pavelić K; Dedivitis RA; Kapitanović S; Cacev T; Guirado CR; Danić D; Radosević S; Brkić K; Pegan B; Krizanac S; Kusić Z; Spaventi S; Bura M
    Mutat Res; 2006 Jul; 599(1-2):45-57. PubMed ID: 16698048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
    Tung WS; Shevlin DW; Bartsch D; Norton JA; Wells SA; Goodfellow PJ
    Mol Carcinog; 1996 Jan; 15(1):5-10. PubMed ID: 8561866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas.
    Pallante P; Visone R; Croce CM; Fusco A
    Endocr Relat Cancer; 2010 Mar; 17(1):F91-104. PubMed ID: 19942715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of survivin in thyroid tumors: differences of expression in well-differentiated, non-well-differentiated, and anaplastic thyroid cancers.
    Pannone G; Santoro A; Pasquali D; Zamparese R; Mattoni M; Russo G; Landriscina M; Piscazzi A; Toti P; Cignarelli M; Lo Muzio L; Bufo P
    Thyroid; 2014 Mar; 24(3):511-9. PubMed ID: 24117205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy: a new hope for thyroid carcinomas.
    Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy.
    Riesco-Eizaguirre G; Santisteban P
    Endocr Relat Cancer; 2007 Dec; 14(4):957-77. PubMed ID: 18045949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Disease: molecular genetics of childhood thyroid cancers.
    Yamashita S; Saenko V
    Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):422-9. PubMed ID: 17452969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
    Xing M
    Endocr Rev; 2007 Dec; 28(7):742-62. PubMed ID: 17940185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.